November 2, 2023
#FutureFresenius continues to provide positive momentum: Fresenius delivers strong third quarter performance and improves operating earnings outlook
read moreNovember 1, 2023
Fresenius Kabi launches Tyenne®*, the first approved tocilizumab biosimilar in the European Union
read moreOctober 31, 2023
Supporting Conscious Choices in Nutritional Care
read moreOctober 25, 2023
Gastrointestinal dysfunction study wins inaugural ESICM Clinical Nutrition Award
read moreSeptember 29, 2023
Fresenius Kabi and Formycon announce EMA Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate
read moreSeptember 19, 2023
Tyenne®*, Fresenius Kabi’s tocilizumab biosimilar, receives European Commission approval
read moreSeptember 15, 2023
Fresenius Kabi recognized as a Top Employer in 2023
read moreSeptember 14, 2023
Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi
read moreSeptember 13, 2023
JUMPstart Clinical Nutrition Award winner announced at ESPEN congress
read moreAugust 24, 2023
Fresenius Kabi and Lupagen enter into strategic development and supply agreement
read moreAugust 17, 2023
Paving the way for the future of blood transfusions
read moreAugust 7, 2023
Fresenius Kabi and Formycon secure U.S. License Date for proposed Ustekinumab biosimilar
read moreAugust 4, 2023
Heroes who save lives: A heartfelt thank you to all blood and plasma donors
read moreAugust 2, 2023
Progress on #FutureFresenius: Operating Companies showing consistent performance; Group simplification delivered
read moreJuly 21, 2023
Fresenius Kabi’s tocilizumab biosimilar candidate MSB11456 receives positive CHMP opinion
read moreJuly 12, 2023
Fresenius Kabi’s denosumab biosimilar candidate FKS518 shows positive clinical trial results
read moreJuly 3, 2023
Fresenius Kabi launches its citrate-free biosimilar Idacio® (adalimumab-aacf) in the United States
read moreJune 14, 2023
The gift of life: A decision to donate blood or plasma
read moreMay 25, 2023
Fresenius SE hosts Kabi Capital Markets Day outlining pathway towards sustainable value creation in line with #FutureFresenius
read moreMay 23, 2023
Fresenius Kabi Awarded Breakthrough Technology Agreement with Premier, Inc. for the Ivenix Infusion System
read moreMay 17, 2023
Fresenius Kabi at the Euroanaesthesia 2023
read moreMay 15, 2023
Fresenius Kabi offers €100,000 grant to advance nutritional care in hospitalized patients
read moreMay 12, 2023
Nurses, our real-life heroes
read moreMay 9, 2023
Fresenius executing on #FutureFresenius: Strong performance of Operating Companies in Q1/23 and structural simplification on track
read moreMay 4, 2023
Help for communities in crisis
read moreApril 24, 2023
Fresenius Kabi Launches Single-Needle Option for the Amicus® Extracorporeal Photopheresis Protocol
read moreApril 17, 2023
Vizient Innovative Technology Contract Awarded to Fresenius Kabi for the Ivenix Infusion System
read moreFebruary 22, 2023
Fresenius strengthens its Management Board team – New appointment at Fresenius Kabi – Expansion of Human Resources/Legal to include ESG
read moreFebruary 21, 2023
Fresenius with new strategy and clear focus
read moreFebruary 16, 2023
Fresenius Kabi launches biosimilar Stimufend® (pegfilgrastim-fpgk) in the U.S.
read moreFebruary 11, 2023
International Day of Women in Science: an interview with JUMPstart winner Lizl Veldsman
read moreFebruary 10, 2023
Fresenius expresses deepest sympathies and commitment to support earthquake victims in Türkiye and Syria
read moreFebruary 9, 2023
Ivenix Infusion System receives Glowing Review by KLAS Research
read moreFebruary 8, 2023
Living with, and managing a chronical disease: A patient’s story
read moreFebruary 2, 2023
Fresenius Kabi announces global license agreement with Formycon AG to commercialize proposed Ustekinumab biosimilar
read moreJanuary 24, 2023
Waterproof ZIP toiletry bag wins Queen Silvia Nursing Award Germany 2022
read moreJanuary 4, 2023
Vision 2026 – Fresenius Kabi’s healthy growth journey
read moreDecember 14, 2022
Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio® (adalimumab)
read moreDecember 12, 2022
JUMPstart 2022 – Committed to driving research in Clinical Nutrition
read moreNovember 16, 2022
A continuous success story: Fresenius Kabi inaugurates extension of its production facilities in Haina
read moreOctober 30, 2022
Fresenius with weak third quarter driven by ongoing challenging macroeconomic environment – FY/22 guidance revised – Charting a new course for Fresenius
read moreOctober 26, 2022
Fresenius Kabi employees around the world team up for breast cancer awareness
read moreOctober 14, 2022
Living life to the fullest thanks to artificial nutrition
read moreOctober 3, 2022
Our new Fresenius CEO Michael Sen outlines what will be essential for #FutureFresenius
read moreSeptember 28, 2022
Learning and creativity for little patients at Children's Cancer Hospital
read moreSeptember 6, 2022
Fresenius Kabi receives U.S. FDA approval for biosimilar Stimufend® (pegfilgrastim)
read moreAugust 19, 2022
Michael Sen to succeed Stephan Sturm as CEO of Fresenius
read moreAugust 18, 2022
Fresenius Kabi announces Acceptance of its Marketing Authorization Application by the European Medicines Agency for MSB11456, a Tocilizumab Biosimilar Candidate
read moreAugust 10, 2022
Fresenius Kabi establishes partnership with Bio-Manguinhos/Fiocruz and Bionovis to provide access to adalimumab biosimilar in Brazil
read moreAugust 2, 2022
Fresenius publishes financial results for the second quarter and first half of 2022 in line with preliminary results
read moreAugust 1, 2022
Fresenius Kabi’s Biologics License Application for Biosimilar Candidate Tocilizumab Accepted for Review by the FDA
read moreAugust 1, 2022
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals market
read moreJuly 27, 2022
Fresenius revises FY/22 Group guidance driven by significantly worsening headwinds at Fresenius Medical Care - Outlook confirmed for Fresenius Kabi, Fresenius Helios and Fresenius Vamed
read moreJuly 27, 2022
A biosimilar patient story: "I can live my life again and not feel fear"
read moreJuly 25, 2022
The Austrian Broadcasting Corporation (ORF) portrayed “The future makers” at Fresenius Kabi Austria
read moreJuly 4, 2022
Ten years of blood donation activity across China – “caring for life” at its best
read moreJune 9, 2022
Further donations to support emergency care of patients in Ukraine
read moreMay 30, 2022
Fresenius Kabi SwissBioSim spreads smiles and happiness with a fundraising campaign
read moreMay 23, 2022
EuroPN Study: New clinical data on medical nutrition therapy in critically ill patients
read moreMay 4, 2022
Fresenius Kabi completes acquisition of Ivenix, Inc., creating an industry-leading infusion therapies offering in the U.S.
read moreMay 4, 2022
Fresenius with solid start to 2022 despite macroeconomic challenges
read moreMay 3, 2022
Fresenius Kabi prolongs the production and supply contract with Cerus Corporation for an additional 10 years
read moreMarch 31, 2022
Next generation patient care: Fresenius Kabi buys a majority stake in mAbxience and acquires Ivenix
read moreMarch 30, 2022
Fresenius Kabi receives European Commission approval for its pegfilgrastim biosimilar Stimufend®
read moreMarch 18, 2022
Update on Humanitarian Aid for Ukraine
read moreMarch 3, 2022
Fresenius Kabi provides humanitarian aid for Ukraine
read moreFebruary 22, 2022
Fresenius delivers a strong finish to the year meeting its improved 2021 guidance – Strategic evaluation shows path to accelerated growth
read moreDecember 13, 2021
Fresenius Kabi modernizes production facility in France
read moreNovember 29, 2021
Innovative €250,000 Parenteral Nutrition Research Grant Awarded by Fresenius Kabi
read moreNovember 2, 2021
Fresenius improves FY/21 Group guidance for the second time after good Q3 results
read moreOctober 19, 2021
Fresenius Kabi wins Fierce Pharma Award 2021
read moreOctober 15, 2021
Time to talk about pumps: Fresenius Kabi supports the World Home Artificial Nutrition Day
read moreSeptember 9, 2021
Video message by CEO Michael Sen for participants of the ESPEN congress 2021
read moreSeptember 7, 2021
Fresenius Kabi’s tocilizumab biosimilar candidate MSB11456 shows positive results in two clinical trials
read moreJuly 30, 2021
Fresenius raises Group earnings guidance after very strong Q2
read moreJuly 7, 2021
Second Parenteral Nutrition Research Grant Latin America winner puts spotlight on the use of supplemental parenteral nutrition in COVID-19 patients
read moreMay 6, 2021
Fresenius with good start to 2021 despite ongoing COVID-19 impact
read moreApril 16, 2021
Second year in a row: Fresenius Kabi in Haina again recognized as Best Place to Work® in the Dominican Republic and in the Caribbean
read moreFebruary 23, 2021
Fresenius achieves 2020 targets and expects healthy business development in 2021 despite ongoing COVID-19 impact
read moreFebruary 10, 2021
At the forefront of innovation: Affordable medicine when we need it most
read moreFebruary 9, 2021
Fresenius Kabi continues to expand its operations in Graz, Austria
read moreFebruary 8, 2021
Honoring achievements in health and nursing management: Fresenius Kabi Germany supports Care Management Award
read moreJanuary 27, 2021
Continued commitment for patient care: Fresenius Kabi Germany supports Queen Silvia Nursing Award
read moreJanuary 22, 2021
Improving the quality of life of homeless people: Fresenius Kabi Germany supports GoBanyo initiative
read moreJanuary 18, 2021
Fresenius Kabi proves resilient in Haina, Dominican Republic
read moreDecember 10, 2020
Further expansion in Dominican Republic – Production site in Haina enlarged by additional warehouse
read moreNovember 18, 2020
Access to affordable healthcare: Fresenius Kabi supports Global Biosimilars Week
read moreNovember 2, 2020
Raising awareness for COVID-19 healthcare measures: Fresenius Kabi initiates Kids Drawing Competition in Indonesia
read moreOctober 29, 2020
Fresenius continues to demonstrate resilience amid the COVID-19 pandemic: FY/20 guidance confirmed given accelerated earnings growth in Q3
read moreOctober 27, 2020
Fresenius Kabi in Haina, Dominican Republic, joins Breast Cancer Awareness Campaign
read moreOctober 14, 2020
Enabling patients to continue their therapy at home: Fresenius Kabi supports the World Home Artificial Nutrition Day
read moreSeptember 18, 2020
Upcoming ESPEN Congress: Malnutrition as constant challenge to the health of patients worldwide
read moreSeptember 16, 2020
ESPEN 2020 - Clinical Nutrition and COVID-19
read moreAugust 20, 2020
Fresenius Kabi starts monthly donation of essential drugs in Brazil to fight COVID-19
read moreJuly 30, 2020
Fresenius: Solid H1 results in light of significant contributions to combat COVID-19 – Accelerated earnings growth expected in H2 – New FY/20 guidance incorporates estimated COVID-19 effects
read moreJuly 2, 2020
Next webinar on COVID-19 and nutrition therapy: Optimizing nutritional care post-hospital discharge
read moreMay 28, 2020
Fresenius Kabi enters marketing agreement for biosimilar product
read moreMay 27, 2020
FDA accepts for review Fresenius Kabi’s first biosimilar regulatory submission for MSB11455, a biosimilar candidate of pegfilgrastim
read moreMay 22, 2020
Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by EMA
read moreMay 7, 2020
Next live webinar for healthcare professionals – Learn more about COVID-19 and nutrition on May 12
read moreMay 6, 2020
Solid start to 2020 – Fresenius proves its resilience in light of significant COVID-19 effects
read moreApril 23, 2020
Second issue of our webinar series about COVID-19 and implications on nutrition coming up on April 28
read moreApril 15, 2020
Fresenius Kabi Germany supports Queen Silvia Nursing Award the eighth consecutive year
read moreApril 7, 2020
Fresenius Kabi takes comprehensive measures to increase supply of essential drugs during COVID-19 pandemic
read moreApril 6, 2020
COVID-19 and implications on nutrition therapy - Join the Fresenius Kabi webinar series
read moreFebruary 20, 2020
Fresenius Kabi and Vifor Pharma create joint venture in China for i.v. iron portfolio
read moreFebruary 20, 2020
Fresenius reports 16th consecutive record year - Significant investments into growth – Healthy growth for 2020 expected – Medium-term growth targets confirmed
read moreFebruary 17, 2020
A new expert consensus publication provides practical guidance on the use of omega-3 fatty acids in parenteral nutrition
read moreJanuary 24, 2020
Fresenius Kabi inaugurates €30 million expansion of transfusion and apheresis disposables plant in Dominican Republic
read moreJanuary 21, 2020
Fresenius Kabi enters into joint venture to advance new cell and gene therapies
read moreDecember 18, 2019
Fresenius Kabi Germany supports children’s hospice and family care service
read moreNovember 22, 2019
Fresenius Kabi Asia Pacific is recognized as an Outstanding Employer by Korn Ferry
read moreNovember 18, 2019
Fresenius Kabi starts United for Clinical Nutrition initiative in Europe with first-of-its-kind clinical study
read moreNovember 14, 2019
Medicines for Europe, APOGEN and Fresenius Kabi hold Open Industry Day in Portugal
read moreNovember 8, 2019
Omega-3 fatty-acid enriched parenteral nutrition improves patient outcomes
read moreOctober 29, 2019
Fresenius confirms guidance after solid third quarter
read moreOctober 23, 2019
Fresenius Kabi expands plant in Brazil
read moreOctober 15, 2019
Fresenius Kabi supports the World Home Artificial Nutrition Day
read moreOctober 8, 2019
Giving back to society - Fresenius Kabi employees celebrate a social day activity in Germany
read moreSeptember 18, 2019
Fresenius Kabi expands biosimilar research activities - Inauguration of state-of-the-art R&D center in Eysins, Switzerland
read moreSeptember 3, 2019
Fresenius Kabi announces winner of parenteral nutrition research grant focused on critical care
read moreAugust 12, 2019
25th Anniversary of the Beijing Fresenius Kabi Pharmaceutical Company
read moreAugust 9, 2019
Fresenius Kabi China celebrated their “Family Day” in Beijing, China
read moreJuly 30, 2019
Fresenius raises Group sales growth guidance after good second quarter
read moreJune 7, 2019
Continuing a 40-years long history in Brazil
read moreMay 23, 2019
“caring for life” by donating blood in China
read moreMay 3, 2019
Fresenius Kabi launches biosimilar adalimumab IDACIO® in Germany
read moreMay 2, 2019
Fresenius makes solid start to 2019 and confirms Group guidance
read moreApril 12, 2019
Fresenius Kabi Germany supports Queen Silvia Nursing Award
read moreApril 3, 2019
Fresenius Kabi receives European Commission approval for adalimumab biosimilar IDACIO®
read moreFebruary 20, 2019
Fresenius reports 15th consecutive record year – Significant investments into medium-term growth in FY/18 and FY/19 – Healthy medium-term growth targets
read moreFebruary 1, 2019
Fresenius Kabi receives positive CHMP opinion for MSB11022, a biosimilar candidate of adalimumab
read moreJanuary 23, 2019
Growing up with parenteral nutrition
read moreNovember 29, 2018
Fresenius Kabi is Among the Most Reputable Companies in Germany
read moreNovember 9, 2018
Watch now: A young man describes the challenges of living with parenteral nutrition and encourages others who are in a similar situation
read moreOctober 30, 2018
Fresenius in Q3/18 with continued strong Group earnings growth in constant currency
read moreOctober 19, 2018
Two Decades as Exceptional Instructor: How Eric Wieschmann creates a reliable pool of talented engineers for Fresenius Kabi
read moreOctober 18, 2018
Fresenius Kabi reaches a global agreement with AbbVie regarding Fresenius Kabi’s adalimumab, MSB11022, a biosimilar candidate of AbbVie’s Humira®
read moreOctober 12, 2018
Fresenius Kabi opens compounding center in Canada
read moreOctober 9, 2018
Fresenius Kabi’s pegfilgrastim biosimilar candidate MSB11455 met its primary endpoints in the two pivotal clinical studies
read moreAugust 10, 2018
Fresenius Kabi is one of the Best Workplaces in the field of Biotechnology, Pharmaceuticals & Healthcare Industry in India
read moreJuly 31, 2018
Fresenius posts strong second quarter and confirms Group guidance – Continued net income growth – EBIT outlook raised for Fresenius Kabi
read moreJune 22, 2018
Fresenius Kabi UK expands operations in Runcorn, England
read moreJune 21, 2018
Melrose Park Topping Out Ceremony
read moreJune 8, 2018
Donating Blood Helps Saving Lives
read moreJune 6, 2018
Fresenius Kabi Australia is the type to save lives
read moreJune 1, 2018
Fresenius Kabi opens new laboratory and office areas at its Innovation & Development Center in Graz, Austria
read moreMay 28, 2018
New EU Commission’s initiative “SPC manufacturing waiver”
read moreMay 16, 2018
Fresenius Kabi is one of the Best Employers in the Czech Republic
read moreMay 9, 2018
Fresenius Kabi USA participates in “Be The Match Walk+Run”
read moreMay 3, 2018
Fresenius makes excellent start to 2018, with strong sales and net income growth in constant currency
read moreApril 20, 2018
Fresenius Kabi expands production site for medical devices in Dominican Republic
read moreApril 13, 2018
Taking on Responsibility
read moreMarch 23, 2018
Fresenius Kabi makes donation to a school in Thailand
read moreMarch 16, 2018
Fresenius Kabi India is certified as a Great Place to Work for in 2018
read moreFebruary 26, 2018
Fresenius reports 14th consecutive record year, aims at strong growth in 2018 and confirms mid-term growth targets
read moreFebruary 9, 2018
The life-changing application: 20 years of loyalty and intense experiences
read moreJanuary 29, 2018
HES solutions should remain on the market
read moreJanuary 22, 2018
Fresenius Kabi’s blood bag plant in Guangzhou, China, celebrates 10th anniversary
read moreDecember 20, 2017
Calea UK and University Hospital Wales support home parenteral nutrition patients
read moreDecember 18, 2017
Fresenius Kabi Submits its First Biosimilar Marketing Authorization Application to European Medicines Agency for MSB11022, a biosimilar of adalimumab
read moreDecember 11, 2017
Fresenius Kabi Germany supports the “wish van” project with Christmas donation
read moreDecember 1, 2017
Fresenius Kabi opens extension at production plant in Mihla, Germany
read moreNovember 24, 2017
Fresenius Kabi opens production facility in Indonesia
read moreNovember 23, 2017
Fresenius Kabi Austria receives “Excellent Company for Learning in Europe” award
read moreNovember 2, 2017
Fresenius reports another strong quarter and confirms guidance
read moreOctober 10, 2017
Fresenius Kabi’s Generic Drugs Business Unit Head elected as president of Medicines for Europe
read moreOctober 10, 2017
Running for patients: Fresenius Kabi Poland goes the extra mile
read moreSeptember 26, 2017
Fresenius Kabi Breaks Ground on $250 million Expansion of Pharmaceutical Manufacturing Site in Illinois
read moreSeptember 25, 2017
Employees of Fresenius Kabi China donate blood together
read moreSeptember 8, 2017
Fresenius Kabi marks 20-year anniversary of Friedberg production site – Logistics center expansion planned
read moreSeptember 6, 2017
Fresenius Kabi Germany supports trainees in geriatric and nursing care
read moreSeptember 1, 2017
Fresenius Kabi completes acquisition of Merck KGaA’s biosimilars business
read moreAugust 1, 2017
Fresenius confirms its guidance after a strong second quarter with double-digit sales and earnings growth
read moreJuly 20, 2017
Akorn shareholders approve merger agreement with Fresenius Kabi - Closing expected latest by early 2018
read moreJuly 6, 2017
Fresenius Kabi expands production site in Portugal
read moreMay 3, 2017
Fresenius is off to an excellent start to the year with strong sales and earnings growth
read moreApril 24, 2017
Fresenius Kabi to strengthen and diversify product portfolio by acquiring Akorn and Merck KGaA’s biosimilars business
read moreApril 4, 2017
Award as “Great Place to Work” in the Dominican Republic
read moreApril 3, 2017
Representative of the U.S. Congress visits the Maricao plant in Puerto Rico
read moreMarch 20, 2017
Fresenius Kabi welcomes Portuguese Minister of Health
read moreMarch 10, 2017
Fresenius Kabi builds new warehouse at Blonie production site
read moreFebruary 22, 2017
Fresenius reports 13th consecutive record year and targets continued strong growth
read moreDecember 21, 2016
Fresenius Kabi Germany supports Blindeninstitut Thüringen (Thuringia Institute for the Blind) with Christmas donation
read moreOctober 27, 2016
Fresenius: Continued strong sales and earnings growth; Lower end of Group earnings guidance raised
read moreOctober 12, 2016
Fresenius Kabi wins award for nutritional therapy website
read moreSeptember 22, 2016
"I want to help others, so they won’t give up" – Living on parenteral nutrition
read moreSeptember 9, 2016
Fresenius Kabi expands production site in Mihla, Germany
read moreAugust 17, 2016
Fresenius Kabi investing nearly $250 million to expand plant near Chicago
read moreAugust 1, 2016
Fresenius raises earnings guidance after strong second quarter; Double-digit earnings growth
read moreJune 27, 2016
Fresenius appoints Stephan Sturm as new Chief Executive Officer – Ulf Mark Schneider leaves the company to pursue another opportunity
read moreJune 16, 2016
Fresenius Kabi USA honored for helping disaster survivors
read moreMay 3, 2016
Strong start into the year – Double-digit earnings growth in constant currency – Fresenius confirms Group guidance for 2016
read moreFebruary 24, 2016
Fresenius: Outstanding 2015 financial results – 25% dividend increase proposed – Positive outlook for 2016 – New mid-term growth targets
read moreJanuary 8, 2016
Fresenius Kabi acquires Ready-to-Administer Drugs and U.S. Pharmaceutical Plant from Becton Dickinson
read moreDecember 4, 2015
Improving the lives of the youth in South Africa
read moreNovember 5, 2015
Fresenius Kabi enhances school facilities in India
read moreOctober 29, 2015
Continued strong sales and net income growth - Fresenius raises Group earnings guidance for 2015
read moreJuly 29, 2015
Accelerating sales and earnings growth in Q2 – Fresenius raises Group earnings guidance for 2015
read moreApril 29, 2015
Strong start into the year – Double-digit growth in constant currency – Fresenius raises Group earnings guidance for 2015
read moreApril 9, 2015
Fresenius Kabi supports medical relief in Gaza and Syria
read moreFebruary 25, 2015
Fresenius: Sales and net income reach all-time highs - 6% dividend increase proposed - Positive Group outlook for 2015
read moreFebruary 16, 2015
Fresenius Kabi sells German oncology compounding business
read moreJanuary 26, 2015
Fresenius Kabi and Halyard Health enter Supply and Distribution Agreement for Halyard Health Elastomeric I.V. Infusion Pumps
read moreJanuary 12, 2015
Fresenius Kabi Receives FDA Status Upgrade for US Grand Island Facility
read moreNovember 17, 2014
Sierra Leone Action Receives Donation of Transfusion Medicine Equipment from Fresenius Kabi
read moreNovember 6, 2014
Fresenius Kabi and Russian partners terminate joint venture agreement
read moreNovember 4, 2014
Fresenius posts strong Q3 results and confirms 2014 Group outlook
read moreSeptember 8, 2014
Blood Collectors Week Celebrates Professionals Who Support the Blood Supply
read moreJuly 31, 2014
Accelerated growth in Q2 - Fresenius raises FY 2014 sales outlook, fully confirms earnings outlook
read moreMay 9, 2014
Fresenius Kabi expands I.V. drug business in Latin America
read moreMay 6, 2014
Fresenius reports expected moderate Q1 2014, fully confirms FY 2014 outlook
read moreApril 25, 2014
Fresenius Kabi enters Russian joint venture
read moreFebruary 25, 2014
Fresenius: Group net income at top end of guidance, exceeding €1 billion – Positive Group outlook for 2014 – New mid-term Group targets
read moreNovember 5, 2013
Continued strong sales and net income growth – Fresenius fully confirms 2013 outlook
read moreOctober 2, 2013
Fresenius Kabi starts joint venture on I.V. generics in Indonesia
read moreAugust 19, 2013
Fresenius Kabi enters joint venture on I.V. generics in Indonesia
read moreJuly 30, 2013
Fresenius announces record results, raises 2013 Group earnings guidance
read moreJuly 25, 2013
Fresenius Kabi receives 60601-1 3rd Edition Certification for Aurora Plasmapheresis System
read moreMay 31, 2013
Fresenius Kabi at the ISBT in Amsterdam
read moreApril 30, 2013
Successful start into 2013 – Fresenius fully confirms outlook
read moreFebruary 26, 2013
Fresenius: Centennial year with record sales and earnings – Group net income exceeds guidance – Positive outlook for 2013
read moreDecember 17, 2012
Fresenius Kabi sells respiratory homecare business in France
read moreDecember 14, 2012
Fresenius Kabi completes acquisition of Fenwal Holdings, Inc.
read moreOctober 31, 2012
Fresenius reports strong sales and earnings growth in the first three quarters and fully confirms 2012 outlook
read moreSeptember 5, 2012
Fresenius Kabi raises 2012 outlook
read moreAugust 1, 2012
Fresenius reports excellent sales and earnings growth, fully confirms 2012 outlook
read moreJuly 20, 2012
Fresenius Kabi acquires Fenwal Holdings, Inc.
read moreJune 11, 2012
Fresenius Kabi Capital Market Day: 2012 outlook raised amid excellent prospects for continued growth
read moreMay 3, 2012
Excellent start into 2012 – Fresenius raises outlook
read moreMarch 9, 2012
Fresenius Announces Management Board Changes
read moreFebruary 21, 2012
Fresenius achieves record sales and earnings in 2011 – Strong growth expected in all business segments for 2012
read moreDecember 2, 2011
Fresenius Kabi announces Changes in the Management Board
read moreNovember 2, 2011
Fresenius achieves record Q3 earnings − improves 2011 earnings outlook
read moreSeptember 26, 2011
Fresenius opens new production facility in Vietnam
read moreAugust 2, 2011
Fresenius: Excellent sales and earnings growth − Fresenius raises earnings outlook
read moreMay 4, 2011
Fresenius: Excellent start into 2011 − Fresenius raises 2011 sales and earnings outlook
read moreFebruary 23, 2011
Fresenius: Record results in 2010: All financial targets met or exceeded – Positive outlook for 2011
read moreNovember 11, 2010
Fresenius Kabi and Boehringer Ingelheim RCV successfully coupled HES to a therapeutic protein in an industrial scale applying Fresenius Kabi’s HESylation® Technology
read moreNovember 2, 2010
Fresenius reports excellent sales and earnings growth – Raises outlook
read moreAugust 3, 2010
Fresenius SE: Excellent sales and earnings growth – Earnings outlook raised
read moreJuly 27, 2010
Fresenius SE: First half of 2010: Preliminary Group net income substantially better than expected − Earnings outlook raised
read moreMay 4, 2010
Fresenius SE: Q1 2010: Successful start into 2010 − Outlook fully confirmed
read moreMarch 26, 2010
MNI Grant for the Best Initiative to Fight Malnutrition
read moreFebruary 24, 2010
Fresenius SE: Record financial results in 2009 − All financial targets met or exceeded − Positive outlook for 2010
read moreJanuary 27, 2010
Fresenius Group’s initial relief assists over 185,000 Haiti earthquake victims
read moreJanuary 13, 2010
Fresenius Kabi and Bayer Schering Pharma extend collaboration regarding HESylation® Technology
read moreNovember 3, 2009
Fresenius SE: Q1-3/2009: Strong organic sales growth achieved - Outlook for 2009 fully confirmed
read moreOctober 28, 2009
Fresenius Kabi and Octapharma Group enter into an Exclusive License, Development and Supply Agreement for a HESylated recombinant protein
read moreAugust 4, 2009
Fresenius SE: H1 2009: Maintains growth momentum: Confirms outlook
read moreMay 18, 2009
Fresenius Kabi and Bayer Schering Pharma enter into a Research, Development and License Agreement regarding HESylation® Technology
read moreApril 30, 2009
Fresenius SE: Q1 2009: Successful start into 2009
read moreFebruary 19, 2009
Fresenius SE: Successful 2008 − Financial targets fully met or exceeded − Positive outlook for 2009
read moreNovember 4, 2008
Fresenius SE: Q1-3/2008: Continued strong growth − Sales outlook raised
read moreSeptember 10, 2008
Fresenius closes APP acquisition
read moreSeptember 2, 2008
Fresenius and APP Pharmaceuticals Announce Clearance of APP Acquisition by U.S. Federal Trade Commission
read moreAugust 11, 2008
Acquisition of Dabur Pharma successfully closed
read moreJuly 30, 2008
Fresenius SE: First half 2008 - Strong financial results
read moreJuly 17, 2008
Strong financial results in the first half of 2008 (preliminary figures)
read moreJuly 7, 2008
Fresenius Kabi to acquire APP Pharmaceuticals – entry into North American I.V. generics market provides excellent growth opportunities
read moreApril 30, 2008
Fresenius SE: Q1 2008 - Successful start into 2008
read moreApril 20, 2008
Fresenius Kabi strengthens its position in i.v. drugs by acquiring Dabur Pharma, a leading manufacturer of oncology generics
read moreFebruary 20, 2008
Fresenius achieves record financial results in 2007 Positive outlook for 2008
read moreDecember 11, 2007
Fresenius Kabi acquires leading European manufacturer of antibiotic agents and strengthens its position in the area of intravenously administered generic drugs
read moreDecember 7, 2007
Fresenius Kabi expands infusion therapy business in Latin America
read moreNovember 26, 2007
Fresenius Kabi continues growth strategy and strengthens its Clinical Nutrition business
read moreOctober 31, 2007
Fresenius SE - Q1-3 2007: Excellent sales and earnings growth in all business segments – Strong third quarter – Outlook raised
read moreAugust 2, 2007
Fresenius SE - First half 2007: Fresenius reports continued growth in sales and earnings and raises full-year earnings outlook
read moreMay 2, 2007
Fresenius AG - Q1 2007: Successful start to 2007
read moreFebruary 22, 2007
Fresenius AG: Fiscal Year 2006
read moreOctober 31, 2006
Fresenius AG - First nine months 2006: Excellent sales and earnings growth in all business segments – Strong third quarter – Outlook raised
read moreOctober 11, 2006
Fresenius plans conversion into European Company (SE) and share split
read moreAugust 3, 2006
Fresenius AG: First half of 2006
read moreMay 3, 2006
Fresenius AG: First quarter 2006
read moreFebruary 22, 2006
Fresenius AG: Fiscal Year 2005
read moreJanuary 3, 2006
Fresenius Kabi raises its stake in Pharmatel Fresenius Kabi Pty Ltd. to 50.1%
read moreNovember 3, 2005
Fresenius AG: Excellent financial results in the 1st- 3rd quarter of 2005; full year outlook confirmed
read moreNovember 1, 2005
Peter Fürst Research Prize
read moreOctober 14, 2005
Fresenius continues profitable growth: Acquisition of Clinico to develop Fresenius Kabi's medical devices business
read moreAugust 4, 2005
First half of 2005: Fresenius achieves excellent financial results and raises full-year earnings outlook
read moreJune 27, 2005
Fresenius Kabi and Pall enter Agreement to Accelerate Adoption of Prion Reduction Technology
read moreMay 4, 2005
First Quarter 2005: Excellent start for Fresenius Group into fiscal year 2005
read moreMarch 17, 2005
Fresenius Kabi recognized by Frost & Sullivan for Competitive Strategy Leadership in Clinical Nutrition
read moreMarch 16, 2005
Fresenius Kabi closed acquisition of I.V. drug company Labesfal
read moreMarch 2, 2005
Fresenius Kabi strengenths position in China - increases stake in joint venture from 65% to 100%
read moreFebruary 24, 2005
Excellent business performance in 2004; Positive outlook for 2005
read moreJanuary 7, 2005
Fresenius Kabi continues growth strategy and acquires I.V. drug company
read moreDecember 8, 2004
Fresenius Kabi: Market leader builds on success
read moreDecember 7, 2004
Fresenius Kabi strengenths position in central and eastern europe
read moreSeptember 6, 2004
Fresenius Kabi is expanding its market presence in Australia
read moreMedia Contacts
At Fresenius Kabi, we welcome your questions, comments and requests. Please fill in the contact form or get in touch with us directly.
Contact Us
Dennis Hofmann
Global Head of Corporate Communications & CSR
+49 6172 686 0
Nicole Weber
Vice President, Corporate Communications & CSR
+49 6172 686 0
Congresses